Literature DB >> 23563173

The transcription intermediary factor 1β coactivates the androgen receptor.

N Van Tilborgh1, L Spans, C Helsen, L Clinckemalie, V Dubois, E Lerut, S Boonen, D Vanderschueren, F Claessens.   

Abstract

The androgen receptor (AR) is a ligand-inducible transcription factor. Its transcription activation domain consists of the two transcription activation units called Tau-1 and Tau- 5. Tau-5 interacts with p160 coactivators like the transcription intermediary factor 2 (TIF2), which in their turn recruit histone modifiers and chromatin-remodelling complexes. The mechanism of action of Tau-1, however, remains elusive. Here, we demonstrate that transcription intermediary factor 1β (TIF1β) can induce the activity of the AR up to five fold when tested in vitro. Although there is no evidence for direct interactions between TIF1β and AR, mutation studies show that the activity of TIF1β depends on the integrity of Tau-1 in AR on the one hand, and the so-called tripartite motif domain in TIF1β on the other. Surprisingly, the coactivation by TIF1β via Tau-1 seems additive rather than cooperative with the AR coactivation by TIF2. Some mutations naturally occurring in androgen-insensitivity syndrome patients that reside in Tau-1 seem to impair the TIF1β coactivation of the AR, indicating that TIF1β could also be relevant for the in vivo androgen response in humans. Moreover, since TIF1β is well expressed in prostate cancer cells, its functional interaction with androgen signalling could in the long run be a therapeutic target for this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563173     DOI: 10.3275/8927

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control.

Authors:  Valerie Christiaens; Charlotte L Bevan; Leen Callewaert; Anna Haelens; Guy Verrijdt; Wilfried Rombauts; Frank Claessens
Journal:  J Biol Chem       Date:  2002-10-04       Impact factor: 5.157

2.  Interplay between two hormone-independent activation domains in the androgen receptor.

Authors:  Leen Callewaert; Nora Van Tilborgh; Frank Claessens
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 3.  Structural basis for nuclear hormone receptor DNA binding.

Authors:  Christine Helsen; Stefanie Kerkhofs; Liesbeth Clinckemalie; Lien Spans; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Mol Cell Endocrinol       Date:  2011-07-27       Impact factor: 4.102

4.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

5.  Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF.

Authors:  I J McEwan; J Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1.

Authors:  C L Bevan; S Hoare; F Claessens; D M Heery; M G Parker
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

7.  Comparison of the molecular consequences of different mutations at residue 754 and 690 of the androgen receptor (AR) and androgen insensitivity syndrome (AIS) phenotype.

Authors:  Rieko Tadokoro; Trevor Bunch; John W R Schwabe; Ieuan A Hughes; Jane C Murphy
Journal:  Clin Endocrinol (Oxf)       Date:  2008-10-26       Impact factor: 3.478

8.  TIF1beta/KAP-1 is a coactivator of the orphan nuclear receptor NGFI-B/Nur77.

Authors:  Juliette Rambaud; Julien Desroches; Aurélio Balsalobre; Jacques Drouin
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

9.  Coactivator TIF1beta interacts with transcription factor C/EBPbeta and glucocorticoid receptor to induce alpha1-acid glycoprotein gene expression.

Authors:  C J Chang; Y L Chen; S C Lee
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

10.  Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.

Authors:  S M Powell; V Christiaens; D Voulgaraki; J Waxman; F Claessens; C L Bevan
Journal:  Endocr Relat Cancer       Date:  2004-03       Impact factor: 5.678

View more
  4 in total

Review 1.  Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients.

Authors:  S Sideris; F Aoun; C N Martinez; S Latifyan; A Awada; G Costante; T Gil
Journal:  J Endocrinol Invest       Date:  2016-01-19       Impact factor: 4.256

2.  Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Authors:  S Stelloo; E Nevedomskaya; Y Kim; L Hoekman; O B Bleijerveld; T Mirza; L F A Wessels; W M van Weerden; A F M Altelaar; A M Bergman; W Zwart
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

3.  TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.

Authors:  Ka-Wing Fong; Jonathan C Zhao; Bing Song; Bin Zheng; Jindan Yu
Journal:  Nat Commun       Date:  2018-11-27       Impact factor: 14.919

4.  TRIM28 is overexpressed in glioma and associated with tumor progression.

Authors:  Chunhai Su; Hui Li; Wenbo Gao
Journal:  Onco Targets Ther       Date:  2018-10-10       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.